Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (474)	11/15/2000 12:00:09 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

From 3Q 10Q file: <<13. Subsequent Event On October 31, 2000, Amgen and Regeneron entered into an agreement whereby Regeneron acquired Amgen's patents and patent applications relating to ciliary neurotrophic factor ("CNTF") and related molecules for $1.0 million. Regeneron then granted back to Amgen exclusive, royalty free rights under these patents and patent applications solely for human ophthalmic uses. In addition, Regeneron entered into a covenant not to sue Amgen under Regeneron's patents and patent applications relating to CNTF and related molecules solely for human ophthalmic uses.>> So, AMGN did give up option to develop CNTF mimetic (like Axokine) as obesity drug. Very good! AMGN still can be good Axokine marketing partner, but I will prefer someone with bit more interest (counting AMGN leptin interest) for obesity field. Miljenko